Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study

Area of Science:

• Oncology
• Hematology
• Biomarker Research

Background:

• Prognostic markers aid in risk stratification for lymphoma patients.
• Identifying novel biomarkers is crucial for developing targeted therapeutic strategies.
• The prognostic value of SPRR1A expression in diffuse large B-cell lymphomas (DLBCL) was previously unestablished.

Purpose of the Study:

• To evaluate the prognostic significance of SPRR1A expression in a large cohort of DLBCL patients.
• To determine if SPRR1A expression can serve as an independent predictor of patient survival.
• To assess the utility of SPRR1A as a biomarker for risk stratification in DLBCL.

Main Methods:

• A cohort of 967 DLBCL patients was analyzed.
• Immunohistochemical analysis was employed to detect SPRR1A expression.
• Kaplan-Meier and multivariate analyses were used to assess survival outcomes.

Main Results:

• SPRR1A expression was detected in 31.54% of the patients.
• Patients with SPRR1A expression had significantly lower 5-year survival rates (26.9% vs. 53.2%, P < 0.001).
• SPRR1A expression was identified as an independent predictor of survival, alongside established factors like LDH level, clinical stage, and histologic subtype.

Conclusions:

• SPRR1A expression is a valuable prognostic factor in diffuse large B-cell lymphoma.
• The presence of SPRR1A expression indicates a poorer prognosis for DLBCL patients.
• SPRR1A holds potential for improving risk stratification and guiding treatment decisions in DLBCL.